Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537134 | 0.81 | ALDH1A1 (0.47) | ALDH1A1CYP2C19LMNAPOLBKMT2A | |
| SCHEMBL787719 | 0.80 | HDAC1 (0.39) | ALDH1A1LMNAHSD17B3HTTTSHR | |
| SCHEMBL787386 | 0.80 | KMT2A (0.40) | POLBKMT2AHTT | |
| SCHEMBL9827897 | 0.78 | MAPT (0.49) | ALDH1A1LMNAPOLBKMT2AMEN1 | |
| SCHEMBL14621343 | 0.78 | MAOA (0.40) | ALDH1A1CYP2C19LMNAPOLBKMT2A | |
| SCHEMBL578432 | 0.76 | NOTUM (0.50) | ALDH1A1CYP2C19KMT2AMEN1 | |
| Paraxazone SCHEMBL2108049 | 0.76 | KMT2A (0.67) | ALDH1A1CYP2C19LMNAPOLBKMT2A | |
| SCHEMBL28412277 | 0.75 | POLB (0.40) | POLBKMT2AMEN1TSHRCYP2C9 | |
| SCHEMBL20548891 | 0.75 | ADRA2A (0.48) | ALDH1A1CYP2C19LMNAPOLBKMT2A | |
| SCHEMBL3785481 | 0.75 | POLB (0.58) | ALDH1A1CYP2C19LMNAPOLBCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | disclosed |
| WO-2010103064-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | PMP22, GRIN2C, NLN | ALDH1A1 670/4885CYP2C19 1277/4885LMNA 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.